Group 1 - The IPO status of Zhuhai Fuji Intelligent Co., Ltd. has changed from "accepted" to "inquiry," with nine key questions raised by the Beijing Stock Exchange regarding the company's governance, compliance, and financial performance [1][2] - The company has no controlling shareholder, with the actual controllers, Lu Shaozhou and Dong Chuntao, holding 32.08% and 31.39% of the shares respectively, and collectively controlling 63.47% of voting rights through a joint action agreement [3] - The company reported revenues of 569 million, 862 million, 975 million, and 542 million yuan for the respective reporting periods, with a significant increase in 2023 attributed to the acquisition of Zhuoyuan's battery cell structure business [3] Group 2 - The company's gross profit margins for the reporting periods were 19.96%, 17.15%, 21.76%, and 22.31%, with a notable increase in 2023 raising questions about the rationale behind this change [4][5] - The Beijing Stock Exchange has requested explanations for the company's lower R&D expense ratio compared to peers, as well as the inconsistency in gross margin trends [6] - The company experienced significant changes in its top five suppliers during the reporting periods, indicating potential volatility in its supply chain [8]

Core Viewpoint - The assessment of Xiansheng Xiangrui's valuation and the rationale behind the acquisition by Beijing Lideman Biochemical Co., Ltd. is deemed reasonable, with a valuation increase rate of 162.23%, which is lower than the average in the biopharmaceutical industry [1][6]. Group 1: Performance Forecast - Xiansheng Xiangrui is projected to achieve a revenue of 582.35 million yuan in 2024, a decrease of approximately 10% year-on-year, with a net profit of 180.14 million yuan, down 14.39% [2]. - The decline in performance is attributed to adjustments in sales models, fiscal constraints in certain regions, and intensified local market competition, although terminal sales are expected to continue growing [2]. - The company is expected to see a non-simulated net profit of 158.76 million yuan in 2024, representing a year-on-year growth of 18.3% [2]. - The market for tuberculosis prevention remains significant, with 696,000 new patients expected in 2024, and the market size for the relevant segment is projected to grow from 2.8 billion yuan in 2024 to 3.5 billion yuan by 2030, with a compound annual growth rate of 4.01% [2]. Group 2: Product and Market Position - Xiansheng Xiangrui's core product, TB-PPD, holds an approximate market share of 83.9% in the skin test market for 2024 [3]. - The company’s IGRA product is expected to be approved and sold by 2025, with other pipeline products like Xs02 progressing well and anticipated to launch by 2027 [3]. - The revenue growth forecast for 2025-2030 is a compound annual growth rate of 3.59%, which is cautious and lower than the industry growth rate [3]. Group 3: Valuation Methodology - The selection of comparable companies in the vaccine industry for market-based assessment is justified, as Xiansheng Xiangrui's core products are similar in management and sales models to vaccine companies [4]. - The assessment process involved selecting four comparable companies from 54 listed bioproduct companies, excluding competitors with a high proportion of agency business [4]. Group 4: Asset Divestiture - The decision to divest mRNA-related assets is considered reasonable, as the company had not achieved marketable R&D results from its mRNA technology platform investment of 41.41 million yuan [5]. - The asset was sold for 83.18 million yuan, generating an investment return of 11.62 million yuan, which is beneficial for focusing on core business and protecting shareholder interests [5]. Group 5: Fairness of Transaction Pricing - The total equity valuation of Xiansheng Xiangrui is assessed at 2.674 billion yuan, with a valuation increase rate of 162.23%, which is within a reasonable range compared to the average increase rate of 338.56% in recent biopharmaceutical transactions [6]. - The final transaction price for 70% of the shares is 1.733 billion yuan, aligning closely with the assessment results, confirming the fairness of the pricing [6].